Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

Redeye: Safeture - ARRhythmia

Safeture

Redeye updates its estimates and valuation following the Q1 2025 report from Safeture. ARR growth was slightly lower than expected, partly due to an FX effect in the quarter. However, with disciplined cost control resulting in positive EBIT for the third quarter in a row, we think the company is in a great spot to reach medium-term annual growth of c15%, in line with the underlying market's development. In our interview with management, we also received confirmation that AXA S.A. was the large client behind the SEK12m deal in late 2023. We adjust our growth estimates in accordance with the lower starting point for ARR following the FX effect, but leave most of our other assumptions untouched. Our fair value range is mostly maintained.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Safeture - ARRhythmia

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.